Keros Therapeutics, Inc. (KROS) — Financial statements
Income statement, balance sheet, and cash flow for Keros Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 244↑6775.0% | 4↑2251.0% | 0.15 | 0.00↓100.0% | 20 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 243↑6732.5% | 4↑2251.0% | 0.15 | 0.00↓100.0% | 20 | |
| Operating Expenses | ||||||
| R&D Expenses | 130↓25.3% | 174↑28.4% | 135↑55.0% | 87↑58.3% | 55 | |
| General & Administrative Expenses | 47↑15.0% | 41↑17.0% | 35↑26.6% | 28↑29.0% | 21 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 47↑15.0% | 41↑17.0% | 35↑26.6% | 28↑29.0% | 21 | |
| Other Expenses | -5 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 172↓19.8% | 214↑26.0% | 170↑48.2% | 115↑50.1% | 76 | |
| Total Costs & Expenses | 173↓19.1% | 214↑26.0% | 170↑48.2% | 115↑50.1% | 76 | |
| Operating Results | ||||||
| Operating Income | 71↑133.5% | -211↓24.1% | -170↓48.0% | -115↓103.6% | -56 | |
| Depreciation & Amortization | 2↑22.8% | 1↑50.8% | 0.82↑20.9% | 0.67↑78.3% | 0.38 | |
| EBITDA | 72↑138.8% | -186↓22.1% | -152↓46.3% | -104↓84.6% | -56 | |
| EBIT | 71↑137.8% | -187↓22.3% | -153↓46.2% | -105↓84.5% | -57 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓75.0% | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -24↓40.3% | -17↓67.6% | -10↓2940.4% | 0.36 | |
| Other Income / Expenses | 21↓10.5% | 24↑40.3% | 17↑67.6% | 10↑2908.6% | -0.36 | |
| Income Before Tax | 92↑149.1% | -187↓22.3% | -153↓46.2% | -105↓84.5% | -57 | |
| Income Tax Expense | 5↑1527.7% | 0.30 | 0.00 | 0.00↓100.0% | 2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 87↑146.4% | -187↓22.5% | -153↓46.2% | -105↓78.2% | -59 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 87↑146.4% | -187↓22.5% | -153↓46.2% | -105↓78.2% | -59 | |
| Bottom-Line Net Income | 87↑146.4% | -187↓22.5% | -153↓46.2% | -105↓78.2% | -59 | |
| EPS (Basic) | 2.34↑146.8% | -5.00↑3.8% | -5.20↓25.3% | -4.15↓64.7% | -2.52 | |
| EPS (Diluted) | 2.30↑146.0% | -5.00↑3.8% | -5.20↓25.3% | -4.15↓64.7% | -2.52 | |
| Weighted Average Shares | 37↓0.6% | 37↑27.1% | 29↑16.7% | 25↑8.2% | 23 | |
| Weighted Average Diluted Shares | 38↑1.1% | 37↑27.1% | 29↑16.7% | 25↑8.2% | 23 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.